Medtronic (MDT) Offering Possible 27.23% Return Over the Next 21 Calendar Days

Medtronic's most recent trend suggests a bullish bias. One trading opportunity on Medtronic is a Bull Put Spread using a strike $96.00 short put and a strike $91.00 long put offers a potential 27.23% return on risk over the next 21 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $96.00 by expiration. The full premium credit of $1.07 would be kept by the premium seller. The risk of $3.93 would be incurred if the stock dropped below the $91.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Medtronic is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Medtronic is bullish.

The RSI indicator is at 78.12 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Medtronic

Medtronic EVP & MITG President Bob White to Speak at Wells Fargo Securities Healthcare Conference
Tue, 28 Aug 2018 15:01:01 +0000
August 28, 2018 – Medtronic plc (MDT), the global leader in medical technology, today announced that it will participate in the 13th Annual Wells Fargo Securities Healthcare Conference on Thursday, September 6, 2018, in Boston. Bob White, executive vice president and president of the Minimally Invasive Therapies Group (MITG) of Medtronic, will answer questions about the company beginning at 10:55 a.m. EDT (9:55 a.m. CDT). Medtronic plc (, headquartered in Dublin, Ireland, is among the world`s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world.

Study Shows Improved Quality of Life and Reduced Symptoms In Patients Treated with Medtronic Cryoballoon
Tue, 28 Aug 2018 13:02:01 +0000
August 28, 2018 – Medtronic plc (MDT) today announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life, reduced symptoms from abnormal heart rhythms, and low incidence of reinterventions and repeat ablation procedures. The study evaluated patients with symptomatic persistent atrial fibrillation (AF) treated with the Medtronic Arctic Front Advance(TM) Cryoballoon, and the results were presented at the 2018 European Society of Cardiology (ESC) Congress in Munich. The Arctic Front Advance Cryoablation System is not approved for treating persistent AF in the United States.

Medtronic CEO Omar Ishrak's compensation up 12 percent
Mon, 27 Aug 2018 19:12:06 +0000
The majority of Ishrak's bump came from a roughly $2 million increase in his non-equity incentive plan.

How Wall Street Analysts View Medtronic after Fiscal Q1 2019
Mon, 27 Aug 2018 13:01:33 +0000
In August, Medtronic launched the IN.PACT Admiral Drug-Coated Balloon in Japan. In 2017, IN.PACT received approval from the Japanese Ministry of Health, Labor and Welfare (or MHLW) for the treatment of individuals with peripheral artery disease in the upper leg (the thigh and behind the knee).

An Update on MDT’s Restorative Therapies after Fiscal Q1 2019
Mon, 27 Aug 2018 11:31:47 +0000
Medtronic’s (MDT) Restorative Therapies Group reported revenue of $1.9 billion in the fiscal first quarter of 2019 compared to $1.8 billion in the fiscal first quarter of 2018, reflecting ~8% YoY (year-over-year) growth. In the quarter, in US, non-US developed, and emerging markets, Medtronic’s Restorative Therapies Group reported revenues of $1.3 billion, $428.0 million, and $227.0 million, respectively, compared to $1.2 billion, $394.0 million, and $194.0 million, respectively, in the fiscal first quarter of 2018, reflecting YoY rises of ~6%, ~9%, and ~17%, respectively. In the quarter, Medtronic’s Spine segment generated revenue of $652.0 million compared to $649.0 million in the fiscal first quarter of 2018. In the US market, the segment reported revenue of $444.0 million, reflecting a ~2% YoY fall.

Be Sociable, Share!

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.